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around the LCA orifice (Fig. 2, middle). This atheroma- 
tous material 'was removed very carefully, creating a wide 
orifice. Then a saphenous vein patch (15 × 10 ram) was 
sutured with 7-0 Prolene sutures from the inferior border 
of the LMT incision up to the junction of the aortic wall, 
terminating 5 mm below the end of the aortotomy. After 
the saphenous vein patch was secured, the entire course of 
the LMT was carefully examined. The transected aorta 
was reconstructed with a continuous 4-0 Prolene suture 
(Fig. 2, bottom). 
The patient was weaned from the pump without difficulty 
and transferred to the intensive care unit in good condition. 
There were no postoperative changes in the electrocardio- 
gram. The recovery was uneventful, and the patient was 
discharged in good condition. Postoperative catheterization 
revealed a large LCA orifice and LMT (Fig. 1). 
Surgical angioplasty of the LMT provides physiologic 
coronary perfusion and good late results without the 
difficulties associated with graft occlusion. 4 Impaired 
LMT flow, however, may result in significant damage to 
the myocardium. 5 Physiologic reconstruction after expo- 
sure of the entire LMT is necessary to provide the best 
flow through this vessel. The "superior approach" de- 
scribed here is an effective way to gain wide exposure of 
the LMT for surgical manipulation. 
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WHOLE BLOOD HEPARIN CONCENTRATION MEASUREMENTS BY AUTOMATED PROTAMINE 
TITRATION AGREE WITH PLASMA ANTI-XA MEASUREMENTS 
G. J. Despotis:, MD, J. H. Joist, MD, PhD, L. T. Goodnough, MD, S. A. Santoro, MD, PhD, and E. Spitznagel, PhD, 
St. Louis, Mo. 
Findings recently reported by our group indicated that 
point-of-care monitoring of heparin concentration by an 
automated protamine sulfate titration (PST) method 
(Hepcon HMS, Medtronic Hemotec, Inc., Englewood, 
Colo.) can reduce excessive microvascular bleeding and 
blood component transfusion] That study was preceded 
by another evaluation in which we found a high degree of 
correlation between heparin concentration determined by 
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plasma anti-Xa and whole blood automated PST. 2 Hardy 
and colleagues 3 recently published a comparison of hep- 
arin measurements by Hepcon automated PST and a 
laboratory-based anti-Xa chromogenic assay in a rela- 
tively small number of patients undergoing cardiac oper- 
ation with the use of cardiopulmonary b pass (CPB). In 
contrast to our observations of a strong linear relationship 
between whole blood PST and plasma anti-Xa measure- 
merits, 2 these investigators found unacceptably high vari- 
ability between the two heparin concentration measure- 
ments. In explaining this discrepancy, Hardy and 
colleagues 3 suggested that our data analysis was limited 
and potentially misleading because we did not use bias 
analysis. We therefore reanalyzed our data with a bias 
analysis method as used by that group. 
Plasma anti-Xa and whole blood PST measurements 
(duplicate) on blood specimens obtained at sequential 
operative times (4 to 6 per patient) from 62 patients 
undergoing cardiac operations were reanalyzed. 2 
Whole blood (WB) PST heparin values were converted 
to plasma equivalent values (PE) using concurrently 
measured hematocrit (Hct) values with the following 
formula: PE WB PST = (WB PST × 100/[100 - Hct]). 
The mean difference or bias between plasma anti-Xa 
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Fig. 1. Bias analysis of plasma anti-Xa versus plasma-equivalent whole blood heparin concentration 
measurements. Heparin concentration i plasma was measured with use of an anti-Xa chromogenic 
assay and whole blood heparin concentration values were measured with an automated PST method 
with use of the Hepcon instrument. Whole blood heparin concentration values were converted to 
plasma equivalent values (PE) with the following formula: PE PST = (PST × 100/[100 - hematocrit]). 
The differences between anti-Xa and whole blood heparin concentration measurements are plotted on 
the y axis and the averages of the two heparin concentration values are plotted on the x axis. The mean 
(bias) and plus or minus two standard eviations of the differences are represented by the horizontal 
lines, n = 310. 
and corrected whole blood PST measurements was 
0.002 +_ 0.53 U/ml. Fig. 1 shows the results of the bias 
analysis with means and two standard eviation confi- 
dence intervals for the 310 measurement pairs. The 
mean difference obtained using duplicate measure- 
ments was similar to those obtained with each of the 
two individual measurements (measurement 1:0.008 _+ 
0.56; measurement 2: -0.004 ± 0.56). 
The findings of this further analysis of our previously 
published data indicate that measurements of heparin 
concentration derived from the Hepcon HMS auto- 
mated protamine titration method agree well with 
laboratory-based anti-Xa measurements of heparin 
concentration when the sensitivity limit of 0.7 U/ml for 
the Hepcon HMS method is applied as suggested by 
Hardy and colleagues. 3 Several factors may account for 
the discrepancy between our findings and those of 
Hardy and colleagues. 3 Most important, in their study, 
hematocrit values used for the conversion of whole 
blood heparin concentration into plasma equivalent 
values were obtained from arterial blood gas analysis 
determined at 30-minute intervals during CPB and not 
from a conventional hemocytometer with blood speci- 
mens obtained simultaneously with those used for 
measurement of heparin concentration (as was done in 
our study), and this may have led to miscalculation of 
plasma-equivalent whole blood heparin concentrations 
as acknowledged by the authors. 3 Differences in stan- 
dardization and performance of laboratory-based 
anti-Xa chromogenic assays may have also contributed 
to the different results obtained by Hardy and col- 
leagues. 3 The wide variability in anti-Xa measurement 
values between various institutibns with low-molecular- 
weight heparin 4 or the inconsistency between laborato- 
ry-based anti-Xa and protamine titration methods, 5 or 
both of these reasons, may also in part account for the 
discrepancy between our Studies. 
Maintenance of adequate, patient-specific heparin con- 
centrations with the use of the Hepcon instrument has 
been shown to reduce excessive hemostatic system activa- 
tion and preserve coagulation factors during CPB, 6 which 
may in part account for the significant reduction in blood 
component transfusion requirements seen with this ap- 
proach. 1In an attempt to explain the benefits found in our 
previous studies, Hardy and colleagues 3 suggested that 
administration of higher heparin and lower protamine 
doses may have accounted for the improved outcomes. 
Although these findings may be the result of administra- 
tion of greater overall heparin doses, the relative impor- 
tance of administering heparin on the basis of patient- 
specific requirements cannot be overlooked. In our 
previous evaluation, 1 the total heparin dose was directly 
related to the concentration ofheparin maintained uring 
CPB that was designated for each patient on the basis of 
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the patient's anticoagulant response to heparin before 
CPB by use of a standard assay (activated clotting time). 
Finally, we have recently evaluated the use of continuous 
infusions of heparin during CPB to maintain stable, 
adequate heparin concentrations. Unpublished ata from 
this study confirm the reliability and usefulness of on-site, 
whole blood heparin concentration measurements by the 
Hepcon HMS system. 
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